Cortes P, Riser B L, Asano K, Rodríguez-Barbero A, Narins R G, Yee J
Department of Medicine, Henry Ford Hospital, Detroit, Michigan, USA.
Kidney Int. 1998 Dec;54(6):1985-98. doi: 10.1046/j.1523-1755.1998.00207.x.
Increased expression of the glucose transporter GLUT1 in mesangial cells (MCs) markedly stimulates glucose transport and the formation of extracellular matrix (ECM), even when ambient glucose concentrations are low. Certain antihyperglycemic agents cause GLUT1 overexpression and increase glucose transport in various tissues. However, their effects on the kidney are unknown. Because diabetic glomerulosclerosis is characterized by the accumulation of mesangial matrix, was studied the effects of antihyperglycemic agents on matrix metabolism in MCs cultured either in 8 or 20 mM glucose.
Membrane-associated GLUT1 was measured by immunoblotting. The initial rate of glucose transport was determined according to the 2-deoxy-D[14C(U)]glucose uptake. Collagen metabolism was studied by metabolic radiolabeling with [14C]-proline. Fibronectin in the medium was measured by ELISA. GLUT1 mRNA was estimated by Northern analysis.
The sulfonylurea tolazamide increased GLUT1 protein expression by 107 and 69% in 8 and 20 mM glucose-grown cells, respectively. However, GLUT1 mRNA levels remained unchanged. Transporter-dependent deoxyglucose uptake was increased by tolazamide up to 184% in a dose-dependent fashion and was evident at both glucose concentrations after three or five days of exposure to the drug. Tolazamide significantly stimulated transforming growth factor-beta 1 (TGF-beta 1) secretion and the total synthesis of collagen and collagen and fibronectin accumulation in the medium of MCs maintained in high or low glucose concentrations. The biguanide metformin did not alter GLUT1 expression, glucose transport, fibronectin formation, or collagen metabolism, except at high concentrations.
Tolazamide markedly enhances ECM synthesis and accumulation in MCs probably by stimulating GLUT1 expression, glucose transport and TGF-beta 1 secretion, irrespective of the ambient glucose concentration. This effect was dose-dependent and minimally inducible by metformin.
即使在环境葡萄糖浓度较低时,系膜细胞(MCs)中葡萄糖转运蛋白GLUT1表达增加也会显著刺激葡萄糖转运和细胞外基质(ECM)形成。某些降糖药会导致GLUT1过表达并增加各种组织中的葡萄糖转运。然而,它们对肾脏的影响尚不清楚。由于糖尿病肾小球硬化的特征是系膜基质积聚,因此研究了降糖药对在8或20 mM葡萄糖中培养的MCs中基质代谢的影响。
通过免疫印迹法测定膜相关GLUT1。根据2-脱氧-D[14C(U)]葡萄糖摄取量测定葡萄糖转运的初始速率。通过用[14C]-脯氨酸进行代谢放射性标记研究胶原蛋白代谢。通过ELISA测定培养基中的纤连蛋白。通过Northern分析估计GLUT1 mRNA。
磺脲类药物甲苯磺丁脲在8和20 mM葡萄糖培养的细胞中分别使GLUT1蛋白表达增加107%和69%。然而,GLUT1 mRNA水平保持不变。甲苯磺丁脲以剂量依赖方式使转运体依赖性脱氧葡萄糖摄取增加高达184%,并且在接触该药物三天或五天后,在两种葡萄糖浓度下均明显增加。甲苯磺丁脲显著刺激转化生长因子-β1(TGF-β1)分泌以及维持在高或低葡萄糖浓度的MCs培养基中胶原蛋白的总合成以及胶原蛋白和纤连蛋白的积累。双胍类药物二甲双胍除了在高浓度时外,不会改变GLUT1表达、葡萄糖转运、纤连蛋白形成或胶原蛋白代谢。
甲苯磺丁脲可能通过刺激GLUT1表达、葡萄糖转运和TGF-β1分泌,显著增强MCs中ECM的合成和积累,而与环境葡萄糖浓度无关。这种作用是剂量依赖性的,且二甲双胍的诱导作用最小。